Chronic Kidney DiseaseNCT07635797
Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients
A study testing Subgingival Instrumentation and Oral Hygiene Instructions in people with Chronic Kidney Disease and Periodontitis, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.
Trial summary
Chronic kidney disease (CKD) and periodontitis share a bidirectional inflammatory relationship, with cytokines such as IL-6, TNF-α, and hsCRP driving progression in both conditions. Read more about this study
- Who is it for?
- Ages 40 to 70 years
- Conditions the study is for
- Chronic Kidney Disease, Periodontitis, End Stage Renal Disease (ESRD)
- What is being tested?
- Subgingival Instrumentation and Oral Hygiene Instructions
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteIndia
- Study dates
- Jul 2026to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients aged 40-70 years.
- Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents.
- Diagnosed with Stage IV or V (eGFR between 15-20 mL/min/1.73m²).
- Not undergoing dialysis.
- Presence of ≥20 natural teeth.
- Diagnosed with moderate (Stage II) (as per 2017 World Workshop classification) (Interdental CAL at site of greatest loss >2mm but <5 mm in ≥ 2 non-adjacent teeth).
- Willingness to provide written informed consent.
Who cannot join
- Patients already undergoing haemodialysis or renal transplantation.
- Patients on insulin therapy or taking SGLT2 inhibitors and GLP-1 receptor agonists.
- HbA1c level >8 %.
- Any Periodontal therapy within past 6 months.
- Immunocompromised patients.
- Any history of tobacco use.
- Pregnant or lactating women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
India1 site
Post Graduate Institute of Dental Sciences , Rohtak
Rohtak, Haryana, 124001
Gurleen Kaur, MDS, 9354031553, drgurleenphd@gmail.com
Vipul Yadav, MDS, 8826363961, vipulyadavv.97@gmail.com
About this study
Official title: Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients: A Non-Randomized Clinical Study
Chronic kidney disease (CKD) and periodontitis share a bidirectional inflammatory relationship, with cytokines such as IL-6, TNF-α, and hsCRP driving progression in both conditions. Non-surgical periodontal therapy (NSPT) has shown reductions in systemic inflammatory markers with emerging evidence of improved renal function, yet robust randomized controlled trials targeting pre-dialysis stage IV-V diabetic CKD patients remain lacking. In the Indian context, where diabetes-related CKD is rapidly rising and access to dialysis is limited, there is a clear lacuna in literature regarding the effectiveness of NSPT in delaying progression to end-stage renal disease. Hence, the present non-randomized clinical study is undertaken to address this gap.
Read the detailed description
Chronic kidney disease (CKD) is a major socio-economic and healthcare problem and represents a significant global public health challenge. The burden of disease is disproportionately higher in low- and middle-income countries. As per the Global Burden of Disease (GBD) 2023 estimates, approximately 788 million people were affected by CKD globally, with a global age-adjusted prevalence of 14.2% among adults aged 20 years and older. CKD has a significant global burden, affecting over 9% of the world population and was directly responsible for 1.2 million deaths worldwide in 2017 alone.
Chronic kidney disease is defined as the presence of kidney damage or an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m² persisting for three months or more, irrespective of the underlying cause. It represents a state of progressive loss of kidney function, ultimately resulting in the need for renal replacement therapy in the form of dialysis or kidney transplantation. Kidney damage refers to pathological abnormalities detected by imaging or renal biopsy, abnormalities in urinary sediment, or increased urinary albumin excretion rates.
The leading cause of CKD is diabetes mellitus, followed by hypertension and glomerular diseases. The prevalence of individuals with CKD due to type 1 diabetes has continued to increase globally, rising by 21.7% between 2007 and 2017 and reaching approximately 3.2 million individuals in 2017. These individuals are at increased risk of cardiovascular complications, and nearly 25-30% progress to kidney failure. Irrespective of the initial nephropathy, once a critical mass of nephrons is lost, kidney disease generally follows a progressive course toward advanced stages, resulting in increased morbidity and mortality.
The burden of CKD arises not only from the management of end-stage renal disease but also from complications related to CKD and its associated comorbidities. There are effective strategies to reduce the rate of CKD progression and improve patient outcomes; therefore, the need for therapies aimed at slowing disease progression is critical.
Periodontal bacteria, which cause chronic inflammation and the breakdown of tooth-supporting structures, are the cause of periodontal disease, a chronic infectious oral illness. One of the most prevalent oral illnesses worldwide is periodontitis, affecting almost 20-50% of the global population in varying degrees, and the percentage rises with advancing age. In India, 51% of people had periodontal disease overall. Periodontal disease is implicated as an independent risk factor for CKD. Periodontitis is defined as an inflammatory disease of the supporting tissues of the teeth caused by specific microorganisms or groups of microorganisms, resulting in progressive destruction of the periodontal ligament and alveolar bone, with periodontal pocket formation, gingival recession, or both.
Chronic kidney disease and periodontal disease are strongly interconnected through shared inflammatory, metabolic, and immune pathways. Periodontal disease has been implicated as an independent risk factor for CKD and may also act as a risk factor for several acquired systemic diseases. The bidirectional relationship between periodontal disease and systemic conditions highlights the importance of oral health assessment in medically compromised populations.
Inflammation is defined as the tissue's biological response to harmful stimuli such as pathogens or irritants. Chronic inflammation and elevated inflammatory markers play a crucial role in the progression and adverse outcomes of CKD. Evidence from previous studies demonstrates that declining renal function is associated with increased levels of circulating inflammatory cytokines. Several investigations have proposed that chronic dental infections, particularly periodontal disease, contribute significantly to the systemic inflammatory burden observed in CKD patients. The pathophysiological concept of periodontitis involves the systemic dissemination of inflammatory mediators such as CRP, IL-6, and tumor necrosis factor-α (TNF-α), either due to local bacterial infection causing periodontal tissue destruction or through the systemic spread of periodontal pathogens and their endotoxins. Periodontitis, being a chronic inflammatory condition, may significantly amplify the existing systemic inflammatory burden in CKD, thereby contributing to disease progression and associated complications.
Periodontal infections worsen the systemic inflammatory status, leading to poor renal outcomes in CKD patients. Improving oral health care through non-surgical periodontal therapy may improve the systemic inflammatory status and renal function. Various studies demonstrated elevated levels of CRP and IL-6 in patients with periodontal disease and their significant reduction following non-surgical periodontal therapy (NSPT). These findings suggest that periodontal intervention may play a role in modulating systemic inflammation.
In the Indian context, where the prevalence of diabetes and CKD is increasing rapidly and access to dialysis remains limited for a large proportion of the population, strategies aimed at delaying progression to end-stage renal disease are of particular importance. Oral health is often neglected in medically compromised individuals, and periodontal disease frequently remains untreated. Addressing periodontal health may therefore represent an overlooked yet impactful component of comprehensive CKD care.
Thus, the present non-randomized controlled study is designed to evaluate the effectiveness of subgingival instrumentation in delaying the progression to end-stage renal disease or the initiation of dialysis among diabetic patients with stage IV chronic kidney disease. By assessing both periodontal and renal parameters over a defined follow-up period of 12 months, this study aims to generate evidence supporting the integration of periodontal care into the comprehensive management of diabetic CKD patients.
- Being tested
- Subgingival Instrumentation, Oral Hygiene Instructions
- Keywords
- Chronic Kidney Disease, Subgingival Instrumentation, Periodontitis, End Stage Renal Disease, Dialysis
- Medical subject headings
- Renal Insufficiency, Chronic, Periodontitis, Kidney Failure, Chronic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Subgingival InstrumentationProcedure or surgery
Participants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and Curettes, GDC) followed by oral hygiene instructions (OHI).
Oral Hygiene InstructionsOther
Participants will receive basic oral hygiene instructions
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Intervention Group participants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and Curettes, GDC) followed by oral hygiene instructions (OHI). Receives: Procedure: Subgingival Instrumentation; Other: Oral Hygiene Instructions |
| Comparator Group | Active comparator | Control group participants will receive basic oral hygiene instructions Receives: Other: Oral Hygiene Instructions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Estimated glomerular filtration rate
Renal function will be assessed by calculating the Estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The CKD-EPI equation incorporates serum creatinine concentration, age, and sex to provide an estimate of kidney function expressed as mL/min/1.73 m².
Measured: Estimated glomerular filtration rate (eGFR) estimation will be performed at 3,6,9 and 12 months.
Soluble Urokinase Plasminogen Activator Receptor(suPAR)
The estimation of soluble urokinase plasminogen activator receptor (suPAR) in plasma will be performed using a sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The assay employs a sandwich ELISA technique, where suPAR in the plasma sample binds to specific antibodies immobilized on the microplate. Following incubation and washing steps, an enzyme-conjugated detection antibody and substrate solution will be added. The enzymatic reaction will produce a measurable colour change proportional to the concentration of suPAR. The absorbance will be recorded at 450 nm using an ELISA microplate reader, and the concentration was calculated using a standard curve.
Measured: The estimation of soluble urokinase plasminogen activator receptor (suPAR) will be done at baseline and 12 months.
Periodontal markers
Different periodontal markers including Pocket Probing Depth(PPD), Clinical Attachment Loss(CAL), Bleeding on Probing(BOP), Calculus Component of Oral Hygiene Index will be estimated.
Measurement will be done at six sites (mesiobuccal, mid-buccal, distobuccal, mesiolingual/palatal, mid-lingual/palatal, and distolingual/palatal) on all maxillary and mandibular teeth.
PPD will be measured from the gingival margin to the base of the pocket, while CAL will be measured from the CEJ to the base of the pocket/sulcus. All the measurements will be rounded to the nearest millimeter and will be recorded using a Williams probe.
For BOP, WHO Probe will be used and bleeding areas will be documented at six sites per tooth.
Measured: Measurement will be done at Baseline, 3, 6, 9 and 12 months.
Renal parameters including Serum creatinine, Serum albumin and Serum urea
Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed.
Serum creatinine levels will be estimated using the Jaffe's kinetic method / enzymatic colorimetric method on an automated biochemistry analyser. The results will be expressed in milligrams per decilitre (mg/dL).
Serum albumin levels will be measured using the bromocresol green (BCG) dye-binding method. The results will be expressed in grams per decilitre (g/dL). The normal reference range for serum albumin will be considered as 3.5-5.0 g/dL.
Serum urea will be estimated using the urease-glutamate dehydrogenase (GLDH) method / diacetyl monoxime method on an automated analyser. The values will be expressed in mg/dL, with a normal reference range of 15-45 mg/dL.
Measured: Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed at baseline,3,6,9 and 12 months.
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis to dialysis.
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be calculated.
Measured: Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be estimated from baseline till 12 month follow up.
Secondary outcomes (2)
High-sensitivity C-reactive protein (hs-CRP)
The concentration of high-sensitivity C-reactive protein (hs-CRP) in plasma will be estimated using a high-sensitivity immunoturbidimetric assay with a commercially available diagnostic kit. Plasma sample will be added to hs-CRP reagent containing anti-CRP antibodies. The mixture will be incubated to allow antigen-antibody complex formation. The change in absorbance will be measured using an automated biochemical analyzer. hs-CRP concentration will be determined using a calibration curve.
Measured: Change in High-sensitivity C-reactive protein (hs-CRP) levels from baseline to 3,6,9 and 12 months will be checked.
Glycated Haemoglobin (HbA1c) levels
Glycated haemoglobin (HbA1c) levels will be measured to assess long-term glycaemic control among study participants. Venous blood samples will be collected and analyzed using standardized laboratory methods. HbA1c reflects the average blood glucose concentration over the preceding 2-3 months and will be expressed as a percentage (%). The measured HbA1c values will be used to evaluate participants' glycaemic status. Assessment will be performed at baseline, 3, 6, 9 and 12 months.
Measured: Glycated haemoglobin (HbA1c) levels assessment will be done at baseline, 3, 6, 9 and 12 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2026
- Study startJul 2026 (estimated)
- Primary completionJul 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Kidney DiseaseStudies of the same condition, open and under way.
- More trials run by Postgraduate Institute of Dental Sciences RohtakThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Postgraduate Institute of Dental Sciences Rohtak
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Vipul Yadav, MDS, Study director, Professor, Department of Public Health Dentistry, Post Graduate Institute of Dental Sciences Rohtak
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07635797
- Sponsor's protocol ID
- Gurleen2676
- Status last verified
- Jun 2026
- First submitted
- 3 Jun 2026
- Last updated
- 18 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Subgingival Instrumentation on Delaying End-stage Renal Disease Among Chronic Kidney Disease Patients: A Non-Randomized Clinical Study
- ClinicalTrials.gov ID
- NCT07635797
- Acronym / sponsor ID
- Gurleen2676
- Keywords
- Chronic Kidney Disease, Subgingival Instrumentation, Periodontitis, End Stage Renal Disease, Dialysis
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Postgraduate Institute of Dental Sciences RohtakUniversity, hospital or other
- Study start
- Jul 2026 (estimated)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 9 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Chronic kidney disease (CKD) and periodontitis share a bidirectional inflammatory relationship, with cytokines such as IL-6, TNF-α, and hsCRP driving progression in both conditions. Non-surgical periodontal therapy (NSPT) has shown reductions in systemic inflammatory markers with emerging evidence of improved renal function, yet robust randomized controlled trials targeting pre-dialysis stage IV-V diabetic CKD patients remain lacking. In the Indian context, where diabetes-related CKD is rapidly rising and access to dialysis is limited, there is a clear lacuna in literature regarding the effectiveness of NSPT in delaying progression to end-stage renal disease. Hence, the present non-randomized clinical study is undertaken to address this gap.
Detailed description
Chronic kidney disease (CKD) is a major socio-economic and healthcare problem and represents a significant global public health challenge. The burden of disease is disproportionately higher in low- and middle-income countries. As per the Global Burden of Disease (GBD) 2023 estimates, approximately 788 million people were affected by CKD globally, with a global age-adjusted prevalence of 14.2% among adults aged 20 years and older. CKD has a significant global burden, affecting over 9% of the world population and was directly responsible for 1.2 million deaths worldwide in 2017 alone.
Chronic kidney disease is defined as the presence of kidney damage or an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73 m² persisting for three months or more, irrespective of the underlying cause. It represents a state of progressive loss of kidney function, ultimately resulting in the need for renal replacement therapy in the form of dialysis or kidney transplantation. Kidney damage refers to pathological abnormalities detected by imaging or renal biopsy, abnormalities in urinary sediment, or increased urinary albumin excretion rates.
The leading cause of CKD is diabetes mellitus, followed by hypertension and glomerular diseases. The prevalence of individuals with CKD due to type 1 diabetes has continued to increase globally, rising by 21.7% between 2007 and 2017 and reaching approximately 3.2 million individuals in 2017. These individuals are at increased risk of cardiovascular complications, and nearly 25-30% progress to kidney failure. Irrespective of the initial nephropathy, once a critical mass of nephrons is lost, kidney disease generally follows a progressive course toward advanced stages, resulting in increased morbidity and mortality.
The burden of CKD arises not only from the management of end-stage renal disease but also from complications related to CKD and its associated comorbidities. There are effective strategies to reduce the rate of CKD progression and improve patient outcomes; therefore, the need for therapies aimed at slowing disease progression is critical.
Periodontal bacteria, which cause chronic inflammation and the breakdown of tooth-supporting structures, are the cause of periodontal disease, a chronic infectious oral illness. One of the most prevalent oral illnesses worldwide is periodontitis, affecting almost 20-50% of the global population in varying degrees, and the percentage rises with advancing age. In India, 51% of people had periodontal disease overall. Periodontal disease is implicated as an independent risk factor for CKD. Periodontitis is defined as an inflammatory disease of the supporting tissues of the teeth caused by specific microorganisms or groups of microorganisms, resulting in progressive destruction of the periodontal ligament and alveolar bone, with periodontal pocket formation, gingival recession, or both.
Chronic kidney disease and periodontal disease are strongly interconnected through shared inflammatory, metabolic, and immune pathways. Periodontal disease has been implicated as an independent risk factor for CKD and may also act as a risk factor for several acquired systemic diseases. The bidirectional relationship between periodontal disease and systemic conditions highlights the importance of oral health assessment in medically compromised populations.
Inflammation is defined as the tissue's biological response to harmful stimuli such as pathogens or irritants. Chronic inflammation and elevated inflammatory markers play a crucial role in the progression and adverse outcomes of CKD. Evidence from previous studies demonstrates that declining renal function is associated with increased levels of circulating inflammatory cytokines. Several investigations have proposed that chronic dental infections, particularly periodontal disease, contribute significantly to the systemic inflammatory burden observed in CKD patients. The pathophysiological concept of periodontitis involves the systemic dissemination of inflammatory mediators such as CRP, IL-6, and tumor necrosis factor-α (TNF-α), either due to local bacterial infection causing periodontal tissue destruction or through the systemic spread of periodontal pathogens and their endotoxins. Periodontitis, being a chronic inflammatory condition, may significantly amplify the existing systemic inflammatory burden in CKD, thereby contributing to disease progression and associated complications.
Periodontal infections worsen the systemic inflammatory status, leading to poor renal outcomes in CKD patients. Improving oral health care through non-surgical periodontal therapy may improve the systemic inflammatory status and renal function. Various studies demonstrated elevated levels of CRP and IL-6 in patients with periodontal disease and their significant reduction following non-surgical periodontal therapy (NSPT). These findings suggest that periodontal intervention may play a role in modulating systemic inflammation.
In the Indian context, where the prevalence of diabetes and CKD is increasing rapidly and access to dialysis remains limited for a large proportion of the population, strategies aimed at delaying progression to end-stage renal disease are of particular importance. Oral health is often neglected in medically compromised individuals, and periodontal disease frequently remains untreated. Addressing periodontal health may therefore represent an overlooked yet impactful component of comprehensive CKD care.
Thus, the present non-randomized controlled study is designed to evaluate the effectiveness of subgingival instrumentation in delaying the progression to end-stage renal disease or the initiation of dialysis among diabetic patients with stage IV chronic kidney disease. By assessing both periodontal and renal parameters over a defined follow-up period of 12 months, this study aims to generate evidence supporting the integration of periodontal care into the comprehensive management of diabetic CKD patients.
Study design
- Primary purpose
- Prevention
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Procedure: Subgingival Instrumentation, Other: Oral Hygiene InstructionsIntervention Group participants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and Curettes, GDC) followed by oral hygiene instructions (OHI). |
| Comparator Group | Active comparator | Other: Oral Hygiene InstructionsControl group participants will receive basic oral hygiene instructions |
Who may qualify
- Ages
- 40 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Patients aged 40-70 years.
- Type 2 diabetes mellitus with chronic kidney disease and currently on oral hypoglycaemic agents.
- Diagnosed with Stage IV or V (eGFR between 15-20 mL/min/1.73m²).
- Not undergoing dialysis.
- Presence of ≥20 natural teeth.
Key exclusion criteria (7 listed)
- Patients already undergoing haemodialysis or renal transplantation.
- Patients on insulin therapy or taking SGLT2 inhibitors and GLP-1 receptor agonists.
- HbA1c level >8 %.
- Any Periodontal therapy within past 6 months.
- Immunocompromised patients.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Subgingival InstrumentationParticipants will receive subgingival instrumentation using an ultrasonic scaler (NSK Variose 2 Ultrasonic Scaler) and hand instruments (Sickle scalers and Curettes, GDC) followed by oral hygiene instructions (OHI). | Procedure or surgery | Intervention Group |
| Oral Hygiene InstructionsParticipants will receive basic oral hygiene instructions | Other | Comparator Group, Intervention Group |
Primary outcome
Estimated glomerular filtration rate
Time frame: Estimated glomerular filtration rate (eGFR) estimation will be performed at 3,6,9 and 12 months.
Renal function will be assessed by calculating the Estimated glomerular filtration rate (eGFR) using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. The CKD-EPI equation incorporates serum creatinine concentration, age, and sex to provide an estimate of kidney function expressed as mL/min/1.73 m².
Soluble Urokinase Plasminogen Activator Receptor(suPAR)
Time frame: The estimation of soluble urokinase plasminogen activator receptor (suPAR) will be done at baseline and 12 months.
The estimation of soluble urokinase plasminogen activator receptor (suPAR) in plasma will be performed using a sandwich Enzyme-Linked Immunosorbent Assay (ELISA). The assay employs a sandwich ELISA technique, where suPAR in the plasma sample binds to specific antibodies immobilized on the microplate. Following incubation and washing steps, an enzyme-conjugated detection antibody and substrate solution will be added. The enzymatic reaction will produce a measurable colour change proportional to the concentration of suPAR. The absorbance will be recorded at 450 nm using an ELISA microplate reader, and the concentration was calculated using a standard curve.
Periodontal markers
Time frame: Measurement will be done at Baseline, 3, 6, 9 and 12 months.
Different periodontal markers including Pocket Probing Depth(PPD), Clinical Attachment Loss(CAL), Bleeding on Probing(BOP), Calculus Component of Oral Hygiene Index will be estimated. Measurement will be done at six sites (mesiobuccal, mid-buccal, distobuccal, mesiolingual/palatal, mid-lingual/palatal, and distolingual/palatal) on all maxillary and mandibular teeth. PPD will be measured from the gingival margin to the base of the pocket, while CAL will be measured from the CEJ to the base of the pocket/sulcus. All the measurements will be rounded to the nearest millimeter and will be recorded using a Williams probe. For BOP, WHO Probe will be used and bleeding areas will be documented at six sites per tooth.
Renal parameters including Serum creatinine, Serum albumin and Serum urea
Time frame: Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed at baseline,3,6,9 and 12 months.
Renal parameters including Serum creatinine, Serum albumin and Serum urea will be assessed. Serum creatinine levels will be estimated using the Jaffe's kinetic method / enzymatic colorimetric method on an automated biochemistry analyser. The results will be expressed in milligrams per decilitre (mg/dL). Serum albumin levels will be measured using the bromocresol green (BCG) dye-binding method. The results will be expressed in grams per decilitre (g/dL). The normal reference range for serum albumin will be considered as 3.5-5.0 g/dL. Serum urea will be estimated using the urease-glutamate dehydrogenase (GLDH) method / diacetyl monoxime method on an automated analyser. The values will be expressed in mg/dL, with a normal reference range of 15-45 mg/dL.
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis to dialysis.
Time frame: Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be estimated from baseline till 12 month follow up.
Percentage of Chronic Kidney Disease patients progressing from pre-dialysis status to dialysis will be calculated.
2 secondary outcomes
High-sensitivity C-reactive protein (hs-CRP)
Time frame: Change in High-sensitivity C-reactive protein (hs-CRP) levels from baseline to 3,6,9 and 12 months will be checked.
Glycated Haemoglobin (HbA1c) levels
Time frame: Glycated haemoglobin (HbA1c) levels assessment will be done at baseline, 3, 6, 9 and 12 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Chronic Kidney Disease
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 3
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
Berger Disease, Bergers Disease
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Not yet recruiting
An Individuation Intervention to Reduce Socioeconomic Disparities in Chronic Kidney Disease Care
Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Vipul Yadav, MDS study director
Professor, Department of Public Health Dentistry, Post Graduate Institute of Dental Sciences Rohtak
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Subgingival Instrumentation and Oral Hygiene Instructions in people with Chronic Kidney Disease and Periodontitis, run by Postgraduate Institute of Dental Sciences Rohtak at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gurleen Kaur, MDS (+91 9354031553, drgurleenphd@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Estimated glomerular filtration rate (time frame: Estimated glomerular filtration rate (eGFR) estimation will be performed at 3,6,9 and 12 months.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jun 2026.